Total Payments
$79,591
2024 Payments
$3,695
Companies
42
Transactions
180
Medicare Patients
19,542
Medicare Billing
$6.0M
Payment Breakdown by Category
Research$37,759 (47.4%)
Consulting$23,388 (29.4%)
Other$11,224 (14.1%)
Food & Beverage$5,204 (6.5%)
Travel$1,510 (1.9%)
Education$507.23 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $37,759 | 27 | 47.4% |
| Consulting Fee | $23,388 | 13 | 29.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,224 | 5 | 12.8% |
| Food and Beverage | $5,204 | 119 | 6.5% |
| Travel and Lodging | $1,510 | 6 | 1.9% |
| Honoraria | $1,000 | 1 | 1.3% |
| Education | $507.23 | 9 | 0.6% |
Payments by Type
General
$41,833
153 transactions
Research
$37,759
27 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $17,642 | 3 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $16,311 | 19 | $0 (2022) |
| Ipsen Biopharmaceuticals, Inc | $10,340 | 14 | $0 (2022) |
| Seattle Genetics, Inc. | $5,362 | 2 | $0 (2019) |
| Seagen Inc. | $4,431 | 6 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $4,066 | 11 | $0 (2024) |
| F. Hoffmann-La Roche AG | $3,656 | 3 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $2,871 | 2 | $0 (2023) |
| Taiho Oncology, Inc. | $2,317 | 7 | $0 (2022) |
| Celgene Corporation | $1,697 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,695 | 36 | ARRAY BIOPHARMA INC ($1,591) |
| 2023 | $3,479 | 20 | JAZZ PHARMACEUTICALS INC. ($2,790) |
| 2022 | $17,422 | 28 | Janssen Scientific Affairs, LLC ($16,200) |
| 2021 | $124.99 | 4 | Celgene Corporation ($77.40) |
| 2020 | $15,716 | 19 | Ipsen Biopharmaceuticals, Inc ($4,685) |
| 2019 | $19,252 | 32 | Eli Lilly and Company ($6,315) |
| 2018 | $17,365 | 20 | Eli Lilly and Company ($11,177) |
| 2017 | $2,536 | 21 | Celgene Corporation ($1,620) |
All Payment Transactions
180 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Education | In-kind items and services | $83.99 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $29.79 | General |
| Category: NONE | ||||||
| 10/24/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $30.02 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $3.40 | General |
| Category: NONE | ||||||
| 09/30/2024 | Iovance Biotherapeutics, Inc. | Amtagvi (Drug) | Food and Beverage | Cash or cash equivalent | $16.91 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $12.74 | General |
| Category: NONE | ||||||
| 09/20/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: Oncology | ||||||
| 09/13/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $21.93 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 09/09/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: NONE | ||||||
| 09/05/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $124.14 | General |
| 08/22/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $4.46 | General |
| Category: NONE | ||||||
| 08/22/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $2.11 | General |
| Category: NONE | ||||||
| 08/20/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Oncology | ||||||
| 08/14/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $9.74 | General |
| Category: NONE | ||||||
| 08/09/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $6.10 | General |
| Category: ONCOLOGY | ||||||
| 07/31/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: NONE | ||||||
| 07/15/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $19.43 | General |
| Category: NONE | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $867.23 | Research |
| Study: TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II • Category: BioOncology | ||||||
| 06/19/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $5.90 | General |
| Category: NONE | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.19 | General |
| Category: Oncology | ||||||
| 06/10/2024 | AstraZeneca Pharmaceuticals LP | IMJUDO (Biological) | Food and Beverage | In-kind items and services | $20.86 | General |
| Category: Oncology | ||||||
| 05/28/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $2.91 | General |
| Category: NONE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $17,492 | 2 |
| MYLUNG | Janssen Scientific Affairs, LLC | $16,200 | 18 |
| ABI-007-PANC-003 | Celgene Corporation | $1,620 | 1 |
| TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II | F. Hoffmann-La Roche AG | $1,326 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $785.42 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $150.00 | 1 |
| A Phase 1 2a Study of BMS 986253 in Combination with Nivolumab in Advanced Cancers | E.R. Squibb & Sons, L.L.C. | $95.00 | 1 |
| An Investigational Immunotherapy Study of BMS 986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | E.R. Squibb & Sons, L.L.C. | $90.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 82 | 4,648 | 116,825 | $8.8M | $1.8M |
| 2022 | 85 | 4,925 | 146,203 | $7.7M | $1.5M |
| 2021 | 84 | 4,741 | 109,264 | $6.8M | $1.4M |
| 2020 | 89 | 5,228 | 111,817 | $6.9M | $1.4M |
Total Patients
19,542
Total Services
484,109
Medicare Billing
$6.0M
Procedure Codes
340
All Medicare Procedures & Services
340 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 38 | 16,200 | $2.2M | $697,937 | 31.6% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 20 | 13,080 | $993,320 | $309,395 | 31.1% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 14 | 5,940 | $760,320 | $226,716 | 29.8% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 24 | 2,550 | $595,290 | $85,834 | 14.4% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 70 | 168 | $464,016 | $45,634 | 9.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 233 | 456 | $322,392 | $44,540 | 13.8% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 69 | 99 | $170,478 | $35,019 | 20.5% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 14 | 1,500 | $232,500 | $34,700 | 14.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 18 | 1,800 | $118,680 | $33,012 | 27.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 312 | 459 | $114,750 | $28,777 | 25.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 108 | 273 | $100,464 | $25,845 | 25.7% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 18 | 264 | $355,872 | $25,266 | 7.1% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 12 | 986 | $178,466 | $23,724 | 13.3% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 15 | 16 | $76,832 | $17,570 | 22.9% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 18 | 5,040 | $100,800 | $11,866 | 11.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 369 | 857 | $54,848 | $8,870 | 16.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 52 | 52 | $36,868 | $8,550 | 23.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 132 | 182 | $56,966 | $8,359 | 14.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 377 | 979 | $19,580 | $8,224 | 42.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 191 | 667 | $72,036 | $7,774 | 10.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 11 | 54 | $198,450 | $7,394 | 3.7% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 39 | 41 | $43,747 | $6,986 | 16.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 92 | 139 | $47,816 | $6,707 | 14.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 362 | 844 | $30,384 | $6,423 | 21.1% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 26 | 16,830 | $84,150 | $6,219 | 7.4% |
About Dr. Donald Richards, MD
Dr. Donald Richards, MD is a Medical Oncology healthcare provider based in Tyler, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659313559.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Donald Richards, MD has received a total of $79,591 in payments from pharmaceutical and medical device companies, with $3,695 received in 2024. These payments were reported across 180 transactions from 42 companies. The most common payment nature is "" ($37,759).
As a Medicare-enrolled provider, Richards has provided services to 19,542 Medicare beneficiaries, totaling 484,109 services with total Medicare billing of $6.0M. Data is available for 4 years (2020–2023), covering 340 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Tyler, TX
- Active Since 06/12/2006
- Last Updated 07/08/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1659313559
Products in Payments
- ONIVYDE (Drug) $8,393
- TAGRISSO (Drug) $3,637
- ZANIDATAMAB $2,790
- Lonsurf (Drug) $2,305
- Onivyde (Drug) $1,960
- Abraxane (Drug) $1,620
- BRAFTOVI (Drug) $1,575
- Kadcyla (Biological) $1,326
- FYARRO (Drug) $1,000
- PEMAZYRE (Drug) $970.00
- Stivarga (Drug) $900.00
- KISQALI (Drug) $839.47
- Nubeqa (Drug) $745.00
- IMBRUVICA (Drug) $382.05
- Prolia (Biological) $319.33
- ZEJULA (Drug) $247.00
- SOMATULINE DEPOT (Drug) $214.06
- DARZALEX (Biological) $159.92
- Cabometyx (Drug) $157.04
- XT CDX (Device) $146.56
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.